Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2009 Apr;32(4):594-6.
doi: 10.2337/dc08-1436.

Insulin therapy and glycemic control in hospitalized patients with diabetes during enteral nutrition therapy: a randomized controlled clinical trial

Mary T Korytkowski  1 , Rose J Salata, Glory L Koerbel, Faith Selzer, Esra Karslioglu, Almoatazbellah M Idriss, Kenneth K W Lee, A James Moser, Frederico G S Toledo
Affiliations
Randomized Controlled Trial

Insulin therapy and glycemic control in hospitalized patients with diabetes during enteral nutrition therapy: a randomized controlled clinical trial

Mary T Korytkowski et al. Diabetes Care. 2009 Apr.

Abstract

Objective: To compare two subcutaneous insulin strategies for glycemic management of hyperglycemia in non-critically ill hospitalized patients with diabetes during enteral nutrition therapy (ENT).

Research design and methods: Fifty inpatients were prospectively randomized to receive sliding-scale regular insulin (SSRI) alone (n = 25) or in combination with insulin glargine (n = 25). NPH insulin was added for persistent hyperglycemia in the SSRI group (glucose >10 mmol/l).

Results: Glycemic control was similar in the SSRI and glargine groups (mean +/- SD study glucose 8.9 +/- 1.6 vs. 9.2 +/- 1.6 mmol/l, respectively; P = 0.71). NPH insulin was added in 48% of the SSRI group subjects. There were no group differences in frequency of hypoglycemia (1.3 +/- 4.1 vs. 1.1 +/- 1.8%; P = 0.35), total adverse events, or length of stay.

Conclusions: Both insulin strategies (SSRI with the addition of NPH for persistent hyperglycemia and glargine) demonstrated similar efficacy and safety in non-critically ill hospitalized patients with type 2 diabetes during ENT.

Trial registration: ClinicalTrials.gov NCT00177398.

PubMed Disclaimer

Comment in

References

    1. Kalfarentzos F, Kehagias J, Mead N, Kokkinis K, Gogos CA: Enteral nutrition is superior to parenteral nutrition in severe acute pancreatitis: results of a randomized prospective trial. Br J Surg 84: 1665– 1669, 1997 - PubMed
    1. Pancorbo-Hidalgo PL, Garcia-Fernandez FP, Ramirez-Perez C: Complications associated with enteral nutrition by nasogastric tube in an internal medicine unit. J Clin Nurs 10: 482– 490, 2001 - PubMed
    1. Umpierrez GE, Isaacs SD, Bazargan N, You X, Thaler LM, Kitabchi AE: Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab 87: 978– 982, 2002 - PubMed
    1. Clement S, Braithwaite SS, Magee MF, Ahmann A, Smith EP, Schafer RG, Hirsch I: Management of diabetes and hyperglycemia in hospitals. Diabetes Care 27: 553– 591, 2004 - PubMed
    1. Cheung NW, Napier B, Zaccaria C, Fletcher JP: Hyperglycemia is associated with adverse outcomes in patients receiving total parenteral nutrition. Diabetes Care 28: 2367– 2371, 2005 - PubMed

Publication types

MeSH terms

Associated data